Shorter (6–9 months), fully oral regimens containing new and repurposed drugs are now the
first-choice option for the treatment of drug-resistant tuberculosis (DR-TB). Clofazimine, long …

Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …

The Comprehensive Resistance Prediction for Tuberculosis: an International Consortium
(CRyPTIC) presents here a data compendium of 12,289 Mycobacterium tuberculosis global …

Background Bedaquiline is a life-saving tuberculosis drug undergoing global scale-up.
People at risk of weak tuberculosis drug regimens are a priority for novel drug access …

Background Bedaquiline improves outcomes of patients with rifampicin-resistant and
multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this …

Mycobacterial pathogens present a significant challenge to disease control efforts globally
due to their inherent resistance to multiple antibiotics. The rise of drug-resistant strains of …

Background Bedaquiline is a core drug for the treatment of multidrug-resistant tuberculosis;
however, the understanding of resistance mechanisms is poor, which is hampering rapid …

Rationale Bedaquiline has been classified as a group A drug for the treatment of multidrug-
resistant tuberculosis (MDR-TB) by the World Health Organization; however, globally …

Multidrug-resistant tuberculosis (MDR-TB) accounts for one third of the annual deaths due to
antimicrobial resistance. Drug resistance-conferring mutations frequently cause fitness costs …

Background Drug-resistant tuberculosis (DR-TB) is considered to be a public health threat
and is difficult to cure, requiring a lengthy treatment with potent, potentially toxic drugs. The …